JP2008513351A - アレルギー疾患の処置のためのＩｇＥ再標的化機能変更分子（ＥＲＦＡＭ） - Google Patents

アレルギー疾患の処置のためのＩｇＥ再標的化機能変更分子（ＥＲＦＡＭ） Download PDF

Info

Publication number
JP2008513351A
JP2008513351A JP2007517532A JP2007517532A JP2008513351A JP 2008513351 A JP2008513351 A JP 2008513351A JP 2007517532 A JP2007517532 A JP 2007517532A JP 2007517532 A JP2007517532 A JP 2007517532A JP 2008513351 A JP2008513351 A JP 2008513351A
Authority
JP
Japan
Prior art keywords
ige
erfam
antibody
composition
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007517532A
Other languages
English (en)
Japanese (ja)
Inventor
ギデオン ドクター ラック，
ビクター ドクター トゥルカーヌ，
Original Assignee
セントメアリーズ ホスピタル エヌエイチエス トラスト
インペリアル カレッジ イノベーションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントメアリーズ ホスピタル エヌエイチエス トラスト, インペリアル カレッジ イノベーションズ リミテッド filed Critical セントメアリーズ ホスピタル エヌエイチエス トラスト
Publication of JP2008513351A publication Critical patent/JP2008513351A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007517532A 2004-05-20 2005-05-19 アレルギー疾患の処置のためのＩｇＥ再標的化機能変更分子（ＥＲＦＡＭ） Withdrawn JP2008513351A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57282104P 2004-05-20 2004-05-20
PCT/IB2005/003950 WO2006048781A2 (fr) 2004-05-20 2005-05-19 Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques

Publications (1)

Publication Number Publication Date
JP2008513351A true JP2008513351A (ja) 2008-05-01

Family

ID=36319549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517532A Withdrawn JP2008513351A (ja) 2004-05-20 2005-05-19 アレルギー疾患の処置のためのＩｇＥ再標的化機能変更分子（ＥＲＦＡＭ）

Country Status (6)

Country Link
EP (1) EP1781269A2 (fr)
JP (1) JP2008513351A (fr)
CN (1) CN101522714A (fr)
AU (1) AU2005300261A1 (fr)
CA (1) CA2566535A1 (fr)
WO (1) WO2006048781A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503007A (ja) * 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
CN103175954A (zh) * 2013-03-08 2013-06-26 北京海瑞祥天生物科技有限公司 人IgE抗体检测试剂盒、制备方法及检测方法
CN103145832B (zh) * 2013-03-21 2015-01-21 江南大学 一种头孢类药物通用人工抗原的合成方法
EP3538558A4 (fr) * 2016-11-09 2020-07-15 North Carolina State University Traitement de maladies allergiques au moyen d'une protéine chimérique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4538192B2 (ja) * 2001-05-01 2010-09-08 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫疾患を治療するための融合分子及び方法
MXPA03011499A (es) * 2001-06-15 2004-04-05 Tanox Inc Proteinas de fusion de fce para el tratamiento de alergia y asma.
US7488804B2 (en) * 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617348B2 (en) 2004-03-26 2017-04-11 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
JP2012503007A (ja) * 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法
US9062117B2 (en) 2008-09-17 2015-06-23 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US9221916B2 (en) 2008-09-17 2015-12-29 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US9266966B2 (en) 2008-09-17 2016-02-23 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US9540451B2 (en) 2008-09-17 2017-01-10 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US11566080B2 (en) 2008-09-17 2023-01-31 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders

Also Published As

Publication number Publication date
AU2005300261A1 (en) 2006-05-11
WO2006048781A3 (fr) 2008-02-14
WO2006048781A2 (fr) 2006-05-11
EP1781269A2 (fr) 2007-05-09
CA2566535A1 (fr) 2006-05-11
CN101522714A (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
RU2731638C2 (ru) Сигнальная система
TWI660972B (zh) 抗ｍｃａｍ抗體及相關使用方法
US5342924A (en) Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
CN104667271B (zh) 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
CA2074089C (fr) Segments extracellulaires des peptides d'ancrage de l'immunoglobuline e humaine, et anticorps specifiques
US5254671A (en) Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US9790271B2 (en) Methods for increasing immunoglobulin A levels
US7604955B2 (en) Immunoglobulin E vaccines and methods of use thereof
JP2008513351A (ja) アレルギー疾患の処置のためのＩｇＥ再標的化機能変更分子（ＥＲＦＡＭ）
JP2004537991A (ja) アレルギー及び喘息治療用Ｆｃε融合タンパク質
ES2212801T3 (es) Peptidos sinteticos y composiciones farmaceuticas que los contienen para el tratamiento del lupus eritematoso sistemico.
JP7461420B2 (ja) 治療抗ＩｇＥ抗体並びにその方法及び組成物
US20060269556A1 (en) Mast cell activation using siglec 6 antibodies
TW202144420A (zh) 一種免疫細胞啟動劑的開發及應用
WO2000023477A2 (fr) Variants d'immunoglobuline
TWI839716B (zh) 抗病毒感染之胜肽疫苗
JP2023542389A (ja) 自己抗体で媒介される状態の予防又は治療のための化合物
JP2023543444A (ja) 重症筋無力症の予防又は治療のための化合物
CN116867807A (zh) Siglec-15结合蛋白的制备及其用途
EP3833442A2 (fr) Anticorps qui se lient à cd277 et leurs utilisations
WO2020033925A2 (fr) Anticorps qui se lient à cd277 et leurs utilisations

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20080805